Cargando…
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod and natalizumab are approved disease-modifying drugs in relapsing–remitting multiple sclerosis (RRMS). The two drugs have different modes of action and may therefore influence different aspects of MS-related tissue damage. In this retrospective cohort study, we longitudinally compared pat...
Autores principales: | Grahl, S., Bussas, M., Wiestler, B., Eichinger, P., Gaser, C., Kirschke, J., Zimmer, C., Berthele, A., Hemmer, B., Mühlau, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804113/ https://www.ncbi.nlm.nih.gov/pubmed/34561843 http://dx.doi.org/10.1007/s13311-021-01118-2 |
Ejemplares similares
-
Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021) -
T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2020) -
Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?
por: Pongratz, Viola, et al.
Publicado: (2019) -
Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume
por: Lauerer, Markus, et al.
Publicado: (2022) -
Lesion location across diagnostic regions in multiple sclerosis
por: Pongratz, Viola, et al.
Publicado: (2023)